武汉费斯德生物科技有限公司, NewEast Biosciences 中国办事处
武汉费斯德生物科技有限公司是美国NewEast Biosciences在中国的办事处。NewEast Biosciences 在十二年前率先研发俩种独特的抗体。这俩种抗体仅仅识别活性的GTP酶或者突变的Oncogene。 GTP酶涉及(1)响应细胞表面受体激活的信号转导,包括跨膜受体,例如介导味觉、嗅觉和视觉的那些,(2)核糖体的蛋白质生物合成,(3)调节细胞分化、增殖、分裂和运动,(4)蛋白质通过膜的易位,(5)细胞内囊泡的运输,以及囊泡介导的分泌和摄取,通过GTP酶控制囊泡外壳组装。Oncogene侧是诱发癌症的基因。
我公司将向你提供以下的独一无二的三种抗体或者试剂盒: (1) 仅识别 GTP酶的活性构型的产品, 它可以让你能够量化GTP酶在细胞中的活性和分布。(2) 识别突变 Oncogene蛋白, 但不认识相应野生型的抗体。 (3) 对 cAMP 和 cGMP 具有超亲和力(无需乙酰化)ELISA检测试剂盒。这些产品被将近一千篇同行评议的文章所引用。
¥1,600.00
货号: 12234 |
产品全名: 人 CGRPR-RAMP1 Full Length 蛋白 |
规格: 10/50/100 µg |
基因符号 CALCRL; CRLR; LMPHM8 |
目标蛋白: CGRPR |
UNIPROT ID: Q16602 |
描述: 人 CGRPR-RAMP1 full length protein membrane nanoparticles (MNPs) |
背景: The CGRP receptor (CGRPR) is a member of family B G protein coupled receptors (GPCRs), is expressed throughout the trigeminal system, including neurons and endothelial cells. They usually function with accessory proteins such as receptor activity modifying proteins (RAMPs) and Na/H exchange regulatory factors (NHERFs). CGRPR is a heterodimer complex of the calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1). Therapeutics for migraine treatment are mostly targeting CRLR-RAMP1 protein-protein interaction surfaces, thereby blocking CGRP activity. |
物种/宿主: HEK293 |
分子量: The human full length CGRPR protein has a MW of 53.0 kDa |
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. |
储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
Figure1. Elisa plates were pre-coated with 0.5 µg/per well purified human CGRPR-RAMP1 full length membrane nanoparticles. Serial diluted anti-CGRPR monoclonal antibody (28157) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CGRPR monoclonal antibody binding with CGRPR-RAMP1 full length membrane nanoparticles is 122.8ng/ml. |